<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Bioorg Med Chem Lett</journal-id>
      <journal-title-group>
        <journal-title>Bioorganic &amp; Medicinal Chemistry Letters</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0960-894X</issn>
      <issn pub-type="epub">1464-3405</issn>
      <publisher>
        <publisher-name>Elsevier Science Ltd</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3235552</article-id>
      <article-id pub-id-type="pmid">21782429</article-id>
      <article-id pub-id-type="publisher-id">BMCL17756</article-id>
      <article-id pub-id-type="doi">10.1016/j.bmcl.2011.06.123</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H<sub>4</sub> and the ion channel serotonin 5-HT<sub>3A</sub></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Verheij</surname>
            <given-names>Mark H.P.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Graaf</surname>
            <given-names>Chris</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Kloe</surname>
            <given-names>Gerdien E.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nijmeijer</surname>
            <given-names>Saskia</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vischer</surname>
            <given-names>Henry F.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smits</surname>
            <given-names>Rogier A.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zuiderveld</surname>
            <given-names>Obbe P.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hulscher</surname>
            <given-names>Saskia</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Silvestri</surname>
            <given-names>Linda</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thompson</surname>
            <given-names>Andrew J.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Muijlwijk-Koezen</surname>
            <given-names>Jacqueline E.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lummis</surname>
            <given-names>Sarah C.R.</given-names>
          </name>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Leurs</surname>
            <given-names>Rob</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Esch</surname>
            <given-names>Iwan J.P.</given-names>
          </name>
          <email>i.de.esch@vu.nl</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="cor1" ref-type="corresp">⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Leiden/Amsterdam Center of Drug Research (LACDR), Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands</aff>
      <aff id="aff2"><label>b</label>Griffin Discoveries BV. De Boelelaan 1083, Room P-246, 1081 HV Amsterdam, The Netherlands</aff>
      <aff id="aff3"><label>c</label>Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>⁎</label>Corresponding author. Address: Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, Room: G-379a, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands. Tel.: +31 205987841; fax: +31 205987610. <email>i.de.esch@vu.nl</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>15</day>
        <month>9</month>
        <year>2011</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>9</month>
        <year>2011</year>
      </pub-date>
      <volume>21</volume>
      <issue>18</issue>
      <fpage>5460</fpage>
      <lpage>5464</lpage>
      <history>
        <date date-type="received">
          <day>2</day>
          <month>5</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>6</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>6</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2011 Elsevier Ltd.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="graphical">
        <title>Graphical abstract</title>
        <fig id="f0030" position="anchor">
          <graphic xlink:href="fx1"/>
        </fig>
      </abstract>
      <abstract>
        <p>A fragment library was screened against the G protein-coupled histamine H<sub>4</sub> receptor (H<sub>4</sub>R) and the ligand-gated ion channel serotonin 5-HT<sub>3A</sub> (5-HT<sub>3A</sub>R). Interestingly, significant overlap was found between H<sub>4</sub>R and 5-HT<sub>3A</sub>R hit sets. The data indicates that dual active H<sub>4</sub>R and 5 HT<sub>3A</sub>R fragments have a higher complexity than the selective compounds which has important implications for chemical genomics approaches. The results of our fragment-based library screening study illustrate similarities in ligand recognition between H<sub>4</sub>R and 5-HT<sub>3A</sub>R and have important consequences for selectivity profiling in ongoing drug discovery efforts on H<sub>4</sub>R and 5-HT<sub>3A</sub>R. The affinity profiles of our fragment screening studies furthermore match the chemical properties of the H<sub>4</sub>R and 5-HT<sub>3A</sub>R binding sites and can be used to define molecular interaction fingerprints to guide the in silico prediction of protein-ligand interactions and structure.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Fragment-based lead discovery (FBLD)</kwd>
        <kwd>Chemogenomics</kwd>
        <kwd>Serotonin 5-HT<sub>3A</sub> receptor</kwd>
        <kwd>Histamine H<sub>4</sub> receptor</kwd>
        <kwd>Dual activity ligand</kwd>
        <kwd>G-protein coupled receptor (GPCR)</kwd>
        <kwd>Ligand gated ion channel (LGIC)</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Fragment-based lead discovery (FBLD) uses low molecular weight compounds as starting points for hit and lead optimization. Compared to the drug-like compounds that are screened in typical high-throughput screening campaigns, fragments are better able to cover the corresponding chemical space. Consequently, typical fragment libraries consist of about 1000 small molecules.<xref rid="b0175" ref-type="bibr"><sup>1</sup></xref> Biochemical and biophysical techniques are used to detect the low affinity fragment binding. Ligand efficiency (LE), defined as the binding energy of the ligand (ΔG in kcal mol<sup>−1</sup>) per non-H atom (Heavy Atoms, HA), is used to select the most promising hits and guide the optimization studies.<xref rid="b0010" ref-type="bibr"><sup>2</sup></xref> Typical hit rates for a fragment library screen are considerably higher than for the high throughput screening of drug-like compounds.<xref rid="b0015" ref-type="bibr"><sup>3</sup></xref> The higher complexity of the latter compounds drastically reduces the chances of perfect complementarity with the biological targets. Thus, fragments are particularly suited to probe the binding site of receptors,<xref rid="b0020 b0025" ref-type="bibr"><sup>4,5</sup></xref> and are therefore ideal tools in chemogenomic approaches that link chemical with biological space.<xref rid="b0030" ref-type="bibr"><sup>6</sup></xref> In chemogenomics studies the effect of a wide array of chemicals on a wide array of biological targets is investigated.<xref rid="b0035" ref-type="bibr"><sup>7</sup></xref> The resulting two-dimensional matrix of targets versus hit compounds is useful for the discovery of ligands for novel drug targets and to have better control over the selectivity of ligands and/or drugs. Furthermore, the data can lead to a better understanding of ligand-receptor interactions.</p>
    <p>We have screened our fragment library against the histamine H<sub>4</sub> receptor (H<sub>4</sub>R) for which we have ongoing drug discovery programs. H<sub>4</sub>R fragment hits were grown into potent H<sub>4</sub>R ligands and fragment-merging approaches resulted in efficient scaffold hopping towards new chemical series.<xref rid="b0040 b0045" ref-type="bibr"><sup>8,9</sup></xref> The H<sub>4</sub>R is considered a very promising target for treating inflammatory and allergic disorders as well in the modulation of pain and pruritis.<xref rid="b0050" ref-type="bibr"><sup>10</sup></xref></p>
    <p>Meanwhile, the same fragment library is being screened against a rapidly expanding variety of targets. Here, we describe a remarkable overlap of the fragment hit set of the H<sub>4</sub>R and the 5-HT<sub>3A</sub>R. This ligand-gated ion channel is a drug target for the treatment of irritable bowel syndrome (IBS) and chemotherapy-induced nausea and vomiting (CINV).<xref rid="b0055" ref-type="bibr"><sup>11</sup></xref> Marketed drugs of 5-HT<sub>3A</sub>R include tropisteron (Navoban®) and palonosetron (Aloxi®). The results of our fragment-based library screening indicate similarities in ligand recognition between H<sub>4</sub>R and 5-HT<sub>3A</sub>R and potential selectivity issues when developing H<sub>4</sub>R or 5-HT<sub>3A</sub>R drugs. On the other side, dual activity compounds might also have clinical advantages. Next to the established role of 5HT<sub>3A</sub>R in IBS, recent findings also suggest a role of H<sub>4</sub>R in this disease. It has been found that an increased innate immune activity in the intestinal mucosa and in blood is found in subpopulations of patients with IBS.<xref rid="b0060" ref-type="bibr"><sup>12</sup></xref> Mast cells and monocytes seem to be particularly important and might indicate that the H<sub>4</sub>R is also involved in this ailment.</p>
    <p>We screened the biological activity of a diverse set of 1010 fragment-like molecules against H<sub>4</sub>R and 5-HT<sub>3A</sub>R. The compounds in this library obey general fragment library rules<xref rid="b0065" ref-type="bibr"><sup>13</sup></xref>: (i) heavy atoms count ⩽ 22; (ii) <italic>c</italic> log <italic>P</italic> &lt;3; (iii) number of H-bond donors ⩽ 3; (iv) number of H-bond acceptors ⩽ 3; (v) number of rotatable bonds ⩽ 5. The fragments furthermore contain at least one ring structure and do not contain reactive functional groups.<xref rid="b0070" ref-type="bibr"><sup>14</sup></xref> The structural diversity of the library was analysed, among others, by means of a scaffold classification analysis (SCA).<xref rid="b0075" ref-type="bibr"><sup>15</sup></xref> In this analysis, fragments are indexed by two parameters, that is, cyclicity and complexity. Cyclicity is the ratio between ring atoms and side chain atoms (thus, if all the atoms of the molecule belong to the ring structure cyclicity equals one). In addition, the complexity was calculated as a descriptor of the size and shape of the scaffold, taking into account the smallest set of smallest rings, the number of heavy atoms, the number of bonds between the heavy atoms, and the sum of heavy atoms atomic number.<xref rid="b0075" ref-type="bibr"><sup>15</sup></xref> Chemical diversity of the fragment library is furthermore confirmed by the fact that only 1.6% of the pair wise comparisons of the ECFP-4 topological fingerprints of the fragments give Tanimoto similarity values higher than 0.26.<xref rid="b0080" ref-type="bibr"><sup>16</sup></xref></p>
    <p>For the H<sub>4</sub>R fragment screen a radioligand displacement study was performed at a 10 μM fragment concentration. Hits were assigned when the fragment displaced 50% or more of the radioligand, resulting in 56 hits (hit rate: 6%). Radioligand binding was measured by displacement of [<sup>3</sup>H]histamine using membranes of HEK293 cells transiently expressing the human H<sub>4</sub>R.<xref rid="b0085" ref-type="bibr"><sup>17</sup></xref> For the hit compounds, affinities were determined by subsequent radioligand displacement studies.</p>
    <p>For the 5-HT<sub>3A</sub>R we performed a high throughput functional fragment screen<xref rid="b0090" ref-type="bibr"><sup>18</sup></xref> using a fluorescent readout (Flex Station) applying a fluorescent membrane potential dye. With this screening technique we can identify compounds that have affinity for the receptor and in addition classify the hits as agonists, antagonists or inactive. From this fragment screening we identified 70 hits for the 5-HT<sub>3A</sub> receptor (hit rate: 7%). Fragments were screened at a concentration of 100 μM using stably expressed human 5-HT<sub>3A</sub>R in HEK293 cells. Binding affinities of hits were determined using radioligand binding studies measuring [<sup>3</sup>H]granisetron binding using membranes of HEK293 cells expressing the human 5-HT<sub>3A</sub>R.<xref rid="b0090" ref-type="bibr"><sup>18</sup></xref></p>
    <p>The SCA plot<xref rid="b0075" ref-type="bibr"><sup>15</sup></xref> in <xref rid="f0005" ref-type="fig">Figure 1</xref>a shows the distribution of 5-HT<sub>3A</sub>R selective hits, H<sub>4</sub>R selective hits, and dual 5-HT<sub>3A</sub>R/H<sub>4</sub>R hits in the chemical space covered by the fragment library and demonstrates the structural diversity of the fragment hits. Interestingly, significant overlap between the H<sub>4</sub>R and 5-HT<sub>3A</sub>R hit sets occur, for example, 24% of the 5-HT<sub>3A</sub>R hits also bind H<sub>4</sub>R and 30% of the H<sub>4</sub>R hits also bind 5-HT<sub>3A</sub>R (<xref rid="f0005" ref-type="fig">Fig. 1</xref>b). This is ca. 10% higher than any other overlap between non-related targets that we have screened so far. In <xref rid="t0005" ref-type="table">Table 1</xref> some selective H<sub>4</sub>R ligands, selective 5-HT<sub>3A</sub>R ligands as well as compounds with affinity for both receptors are displayed. Dual hits <bold>7</bold>, <bold>8</bold>, <bold>11</bold> have comparable affinities for 5-HT<sub>3</sub>R and H<sub>4</sub>R, while dual hit <bold>9</bold> has 500-fold selectivity for 5-HT<sub>3</sub>R over H<sub>4</sub>R, and hit <bold>10</bold> has 200-fold for H<sub>4</sub>R over 5-HT<sub>3</sub>R (<xref rid="t0005" ref-type="table">Table 1</xref>).</p>
    <p>Many of the dual H<sub>4</sub>R/5-HT<sub>3A</sub>R ligands contain a quinazoline, quinoxaline, aminopyrimidine, imidazole, or benzimidazole scaffold in combination with a positively ionizable ring system (<xref rid="t0005" ref-type="table">Table 1</xref>). <xref rid="f0005" ref-type="fig">Figure 1</xref>c shows that most of these dual H<sub>4</sub>R/5-HT<sub>3A</sub>R fragments have a higher complexity than the H<sub>4</sub>R and 5-HT<sub>3A</sub>R selective fragments. The structural complexity of 71% of the dual 5-HT<sub>3A</sub>/H<sub>4</sub>R fragments is 0.7 or higher, while 79% of the H<sub>4</sub>R selective hits and 74% of the 5-HT<sub>3A</sub>R selective fragments is lower than 0.7. While earlier chemoinformatics analyses suggested that selective ligands are more complex in terms of pharmacophore features<xref rid="b0020" ref-type="bibr"><sup>4</sup></xref> and molecular shape<xref rid="b0095" ref-type="bibr"><sup>19</sup></xref>, our fragment-based chemogenomics study suggests a more delicate balance between ligand complexity and target selectivity. Our fragment library screening data indicate that fragments need to have high enough complexity to hit several targets, but low enough complexity to be too specific for a single site. This is in line with the theoretical model by Hann and co-workers<xref rid="b0020" ref-type="bibr"><sup>4</sup></xref> that describes probability of finding a hit when considering the complexity of the ligand. The probability of detecting a binding event is given by multiplying the probability of matching features and the probability of being able to detect low affinity binders. Our experimental data set shows that indeed the chance of finding fragment hits on two different targets favors higher complexity compounds. The relatively high complexity of the overlapping H<sub>4</sub>R and 5-HT<sub>3A</sub>R fragment hit set is furthermore a clear indication that the ligand recognition profiles of these receptors are similar. <xref rid="f0010" ref-type="fig">Figure 2</xref> shows the chemical similarity of the fragment library compared to serotonin and histamine (determined by Pipeline Pilot ECFP-4 circular fingerprint<xref rid="b0100" ref-type="bibr"><sup>20</sup></xref> Tanimoto similarity coefficients (Tc)). While some of the H<sub>4</sub>R selective fragments (38%) are chemically similar to histamine (i.e., ECFP-4 Tc &gt;0.26 including <bold>2</bold> (<xref rid="t0005" ref-type="table">Table 1</xref>)), none of the 5-HT<sub>3A</sub>R selective fragments share chemical similarity serotonin-like, and only two of the dual binders are histamine-like (including <bold>11</bold> see <xref rid="t0005" ref-type="table">Table 1</xref>). These data show that complex H<sub>4</sub>R/5-HT<sub>3A</sub>R dual fragments are dissimilar from the (less complex) endogenous ligands of H<sub>4</sub>R and 5-HT<sub>3A</sub>R.</p>
    <p>The higher complexity of the dual H<sub>4</sub>R and 5-HT<sub>3A</sub>R fragments is further illustrated by the analysis of the physical-chemical distributions of fragment hits (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). Whereas most properties are similar when comparing the selective and the dual activity fragments (see <xref rid="s0010" ref-type="sec">Table S1, S2 and Figure S1</xref> for details<xref rid="b0180" ref-type="bibr"><sup>21</sup></xref>), the number of rings and the heavy atom count (and associated molecular weight) are higher for the dual activity hits compared to for H<sub>4</sub>R and 5-HT<sub>3A</sub>R selective fragments (<xref rid="f0015" ref-type="fig">Fig. 3</xref> and Table S2).</p>
    <p>The fragment screening does not only illustrate similarities in H<sub>4</sub>R and 5-HT<sub>3A</sub>R binding profiles, but also identifies subtle differences between the properties of selective receptor ligands. <xref rid="f0015" ref-type="fig">Figure 3</xref> shows that the number of H-bond donor atoms is significantly higher for the H<sub>4</sub>R selective fragments (on average 1.7 H-bond donors) than for 5-HT<sub>3A</sub>R selective fragments (on average 0.8 H-bond donors). This can be correlated with the H<sub>4</sub>R ligand pharmacophore<xref rid="b0110" ref-type="bibr"><sup>22</sup></xref> that contains two H-bond donors. In the H<sub>4</sub>R binding pocket, these features are complementary to two negatively charged residues, D3.32 and E5.46 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>).<xref rid="b0110" ref-type="bibr"><sup>22</sup></xref> As a result of these strong non-hydrophobic interactions<xref rid="b0115" ref-type="bibr"><sup>23</sup></xref> between ionizable H-bonding partners, many H<sub>4</sub>R ligands (including the high affinity endogenous ligand histamine) can bind the receptor with a high lipophilic efficiency,<xref rid="b0120" ref-type="bibr"><sup>24</sup></xref> explaining the relatively low <italic>c</italic> log <italic>P</italic> values of H<sub>4</sub>R ligand (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). In the 5-HT<sub>3A</sub>R binding pocket one essential glutamate H-bond interaction partner (E129) has been identified (<xref rid="f0020" ref-type="fig">Fig. 4</xref>).<xref rid="b0125" ref-type="bibr"><sup>25</sup></xref> Ligand binding to 5-HT<sub>3A</sub>R is furthermore largely determined by aromatic interactions like π–π stacking and cation-π interactions (W183, W195, Y141, Y143, Y153, Y234, see <xref rid="f0020" ref-type="fig">Fig. 4</xref>)<xref rid="b0125 b0130" ref-type="bibr"><sup>25,26</sup></xref>, matching the requirement of a lower number of H-bond donors (and somewhat higher hydrophobicity) for 5-HT<sub>3A</sub>R ligands compared to H<sub>4</sub>R ligands. In line with the notion that the H<sub>4</sub>R binding site contains two essential H-bonding acceptor atoms and the 5-HT<sub>3A</sub>R site only one such atom, is the observation that fragment <bold>10</bold> possesses affinity for both 5-HT<sub>3A</sub>R and H<sub>4</sub>R, whereas the analogous fragment <bold>3</bold> that lacks an NH<sub>2</sub> group, only shows affinity for the H<sub>4</sub>R.</p>
    <p><xref rid="f0020" ref-type="fig">Figure 4</xref> demonstrates how the affinity profiles from our fragment screening studies correspond with the chemical properties of the H<sub>4</sub>R and 5-HT<sub>3A</sub>R binding sites and can be used to derive molecular interaction fingerprints<xref rid="b0135" ref-type="bibr"><sup>27</sup></xref> and validate structural models of protein-ligand complexes.<xref rid="b0140" ref-type="bibr"><sup>28</sup></xref> In both H<sub>4</sub>R<xref rid="b0085" ref-type="bibr"><sup>17</sup></xref> and 5-HT<sub>3A</sub>R models (see <xref rid="s0010" ref-type="sec">Supplementary data</xref> for a description of the protein modeling procedure), the positively ionizable piperazine group of the dual H<sub>4</sub>R/5-HT<sub>3A</sub>R hit <bold>8</bold> forms a salt bridge (D3.32 in H<sub>4</sub>R, E129 in 5-HT<sub>3A</sub>R) and makes cation-π (F7.39 in H<sub>4</sub>R, Y234 and W183 in 5-HT<sub>3A</sub>R) and aromatic π–π stacking interactions (Y3.33 and Y6.51 in H<sub>4</sub>R, Y153 in 5-HT<sub>3A</sub>R). Interestingly, while C3.36 and E5.46 are proposed to act as H-bond donor and acceptor to the carboxamide group of <bold>10</bold> in H<sub>4</sub>R, two water molecules (which form a conserved protein-ligand H-bond interaction network in several crystal structures of the homologous AChBP<xref rid="b0145" ref-type="bibr"><sup>29</sup></xref>) fulfill the same role in 5-HT<sub>3A</sub>R. The binding mode modes of <bold>8</bold> presented in <xref rid="f0020" ref-type="fig">Figure 4</xref> do not only match the fragment-based chemogenomics analysis reported in the current study, but are also supported by earlier reported site-directed mutagenesis studies, underlining the important role of E129, W183, Y153, and Y234<xref rid="b0125 b0130" ref-type="bibr"><sup>25,26</sup></xref> in ligand binding to 5-HT<sub>3A</sub>R, and the essential role of D3.32 and E5.46 in H<sub>4</sub>R-ligand interactions.<xref rid="b0110 b0115 b0120" ref-type="bibr"><sup>22–24</sup></xref> The binding orientation of <bold>8</bold> is furthermore in line with previously experimentally validated ligand binding modes in H<sub>4</sub>R.<xref rid="b0085" ref-type="bibr"><sup>17</sup></xref></p>
    <p>Chemogenomics analyses of inter-gene family ligand promiscuity is of growing interest.<xref rid="b0150" ref-type="bibr"><sup>30</sup></xref> Although GPCRs and LGICs obviously have a very different protein architecture, their ligand-binding sites can obviously bind similar (sub)structures. In this respect, the special chemical taxonomy of serotonin, that binds to several GPCRs and one ion-channel (5-HT<sub>3A</sub>) has been previously noted.<xref rid="b0155" ref-type="bibr"><sup>31</sup></xref> Moreover, Mestres and co-workers have recently reported a striking cross-pharmacology between aminergic GPCRs and the 5-HT<sub>3</sub> receptors in their <italic>in silico</italic> target profiling platform.<xref rid="b0160" ref-type="bibr"><sup>32</sup></xref> Our fragment screening studies complement these findings by identifying relatively high fragment cross-reactivity between H<sub>4</sub>R and 5-HT<sub>3A</sub>R (<xref rid="f0005" ref-type="fig">Fig. 1</xref>b) and demonstrate that fragments are ideally suited to interrogate ligand binding sites. In the hit optimization phase, selectivity for either H<sub>4</sub>R or 5-HT<sub>3A</sub>R can be achieved, although in some cases this might proof complicated. This is illustrated by recent publications from Abbott Laboratories.<xref rid="b0165 b0170" ref-type="bibr"><sup>33,34</sup></xref> These studies, that are part of their H<sub>4</sub>R drug development program, describe the in vitro and in vivo characterization of the H<sub>4</sub>R ligands <bold>12</bold> and <bold>13</bold> (A-940894). Intriguingly, both these compounds (<xref rid="f0025" ref-type="fig">Fig. 5</xref>) show strong inhibition at the 5-HT<sub>3A</sub>R receptor (98% inhibition at 10 μM). It is noted that these compounds contain the 2-amino-4-piperazine-pyrimidine scaffold that was also identified as binding to both H<sub>4</sub>R and 5-HT<sub>3A</sub>R in our fragment-screening (fragment 10, <xref rid="t0005" ref-type="table">Table 1</xref>).</p>
    <p>In conclusion, the present study identifies a significant overlap between the hit fragment set for H<sub>4</sub>R and 5-HT<sub>3A</sub>R, illustrating similarities in ligand recognition and suggests that fragment-based chemogenomics analysis and molecular modeling building can be used to efficiently navigate chemical space during hit optimization in programs aimed to develop selective leads or compounds with a dual activity profile.</p>
  </body>
  <back>
    <ref-list>
      <title>References and notes</title>
      <ref id="b0175">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Kloe</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>de Esch</surname>
              <given-names>I.J.</given-names>
            </name>
          </person-group>
          <source>Drug Discovery Today</source>
          <volume>14</volume>
          <year>2009</year>
          <fpage>630</fpage>
          <pub-id pub-id-type="pmid">19443265</pub-id>
        </element-citation>
      </ref>
      <ref id="b0010">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hopkins</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Groom</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Alex</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <source>Drug Discovery Today</source>
          <volume>9</volume>
          <year>2004</year>
          <fpage>430</fpage>
          <pub-id pub-id-type="pmid">15109945</pub-id>
        </element-citation>
      </ref>
      <ref id="b0015">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuffenhauer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ruedisser</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Marzinzik</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Jahnke</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Blommers</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Selzer</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Jacoby</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Curr. Top. Med. Chem.</source>
          <volume>5</volume>
          <year>2005</year>
          <fpage>751</fpage>
          <pub-id pub-id-type="pmid">16101415</pub-id>
        </element-citation>
      </ref>
      <ref id="b0020">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hann</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Leach</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <source>J. Chem. Inf. Comput. Sci.</source>
          <volume>41</volume>
          <year>2001</year>
          <fpage>856</fpage>
          <pub-id pub-id-type="pmid">11410068</pub-id>
        </element-citation>
      </ref>
      <ref id="b0025">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hajduk</surname>
              <given-names>P.J.</given-names>
            </name>
            <name>
              <surname>Huth</surname>
              <given-names>J.R.</given-names>
            </name>
            <name>
              <surname>Tse</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <source>Drug Discovery Today</source>
          <volume>10</volume>
          <year>2005</year>
          <fpage>1675</fpage>
          <pub-id pub-id-type="pmid">16376828</pub-id>
        </element-citation>
      </ref>
      <ref id="b0030">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Hubbard</surname>
              <given-names>R.E.J.</given-names>
            </name>
          </person-group>
          <source>Comput. Aided Mol. Des.</source>
          <volume>23</volume>
          <year>2009</year>
          <fpage>603</fpage>
        </element-citation>
      </ref>
      <ref id="b0035">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rognan</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Br. J. Pharmacol.</source>
          <volume>152</volume>
          <year>2007</year>
          <fpage>38</fpage>
          <pub-id pub-id-type="pmid">17533416</pub-id>
        </element-citation>
      </ref>
      <ref id="b0040">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smits</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>de Esch</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Zuiderveld</surname>
              <given-names>O.P.</given-names>
            </name>
            <name>
              <surname>Broeker</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Sansuk</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Guaita</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Coruzzi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Adami</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Haaksma</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>51</volume>
          <year>2008</year>
          <fpage>7855</fpage>
          <pub-id pub-id-type="pmid">19053770</pub-id>
        </element-citation>
      </ref>
      <ref id="b0045">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smits</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>H.D.</given-names>
            </name>
            <name>
              <surname>Hanzer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zuiderveld</surname>
              <given-names>O.P.</given-names>
            </name>
            <name>
              <surname>Guaita</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Adami</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Coruzzi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>de Esch</surname>
              <given-names>I.J.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>51</volume>
          <year>2008</year>
          <fpage>2457</fpage>
          <pub-id pub-id-type="pmid">18357976</pub-id>
        </element-citation>
      </ref>
      <ref id="b0050">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Westly</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <source>Nat. Med.</source>
          <volume>16</volume>
          <year>2010</year>
          <fpage>1063</fpage>
          <pub-id pub-id-type="pmid">20930737</pub-id>
        </element-citation>
      </ref>
      <ref id="b0055">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Lummis</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <source>Expert Opin. Ther. Targets</source>
          <volume>11</volume>
          <year>2007</year>
          <fpage>527</fpage>
          <pub-id pub-id-type="pmid">17373882</pub-id>
        </element-citation>
      </ref>
      <ref id="b0060">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohman</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Simren</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <source>Nat. Rev. Gastroenterol. Hepatol.</source>
          <volume>7</volume>
          <year>2010</year>
          <fpage>163</fpage>
          <pub-id pub-id-type="pmid">20101257</pub-id>
        </element-citation>
      </ref>
      <ref id="b0065">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Siegal</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Ab</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Schultz</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Drug Discovery Today</source>
          <volume>12</volume>
          <year>2007</year>
          <fpage>1032</fpage>
          <pub-id pub-id-type="pmid">18061882</pub-id>
        </element-citation>
      </ref>
      <ref id="b0070">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oprea</surname>
              <given-names>T.I.</given-names>
            </name>
          </person-group>
          <source>J. Comput. Aided Mol. Des.</source>
          <volume>14</volume>
          <year>2000</year>
          <fpage>251</fpage>
          <pub-id pub-id-type="pmid">10756480</pub-id>
        </element-citation>
      </ref>
      <ref id="b0075">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>45</volume>
          <year>2002</year>
          <fpage>5311</fpage>
          <pub-id pub-id-type="pmid">12431058</pub-id>
        </element-citation>
      </ref>
      <ref id="b0080">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Steffen</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Kogej</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Tyrchan</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Engkvist</surname>
              <given-names>O.</given-names>
            </name>
          </person-group>
          <source>J. Chem. Inf. Model</source>
          <volume>49</volume>
          <year>2009</year>
          <fpage>338</fpage>
          <pub-id pub-id-type="pmid">19434835</pub-id>
        </element-citation>
      </ref>
      <ref id="b0085">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>H.D.</given-names>
            </name>
            <name>
              <surname>de Graaf</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Sadek</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McGovern</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Istyastono</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Bakker</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>de Esch</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Thurmond</surname>
              <given-names>R.L.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>Mol. Pharmacol.</source>
          <volume>77</volume>
          <year>2010</year>
          <fpage>734</fpage>
          <pub-id pub-id-type="pmid">20103609</pub-id>
        </element-citation>
      </ref>
      <ref id="b0090">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thompson</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Verheij</surname>
              <given-names>M.H.P.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>De Esch</surname>
              <given-names>I.J.P.</given-names>
            </name>
            <name>
              <surname>Lummis</surname>
              <given-names>S.C.R.</given-names>
            </name>
          </person-group>
          <source>Biotechniques</source>
          <volume>49</volume>
          <year>2010</year>
          <fpage>8</fpage>
        </element-citation>
      </ref>
      <ref id="b0095">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clemons</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Bodycombe</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Carrinski</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Shamji</surname>
              <given-names>A.F.</given-names>
            </name>
            <name>
              <surname>Wagner</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Koehler</surname>
              <given-names>A.N.</given-names>
            </name>
            <name>
              <surname>Schreiber</surname>
              <given-names>S.L.</given-names>
            </name>
          </person-group>
          <source>Proc. Natl. Acad. Sci. U.S.A.</source>
          <volume>107</volume>
          <year>2010</year>
          <fpage>18787</fpage>
          <pub-id pub-id-type="pmid">20956335</pub-id>
        </element-citation>
      </ref>
      <ref id="b0100">
        <label>20</label>
        <mixed-citation publication-type="other">Accelrys Software Inc. S. D., C., USA.</mixed-citation>
      </ref>
      <ref id="b0180">
        <label>21</label>
        <note>
          <p>Distributions of physical-chemical properties of fragment hits and experimental details of H4R and 5-HT3AR screens are available in the <xref rid="s0010" ref-type="sec">Supplementary data</xref></p>
        </note>
      </ref>
      <ref id="b0110">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jongejan</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>H.D.</given-names>
            </name>
            <name>
              <surname>Smits</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>de Esch</surname>
              <given-names>I.J.</given-names>
            </name>
            <name>
              <surname>Haaksma</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Leurs</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <source>J. Chem. Inf. Model</source>
          <volume>48</volume>
          <year>2008</year>
          <fpage>1455</fpage>
          <pub-id pub-id-type="pmid">18553960</pub-id>
        </element-citation>
      </ref>
      <ref id="b0115">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shamovsky</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>de Graaf</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Alderin</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Bengtsson</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bladh</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Borjesson</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Connolly</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Dyke</surname>
              <given-names>H.J.</given-names>
            </name>
            <name>
              <surname>van den Heuvel</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Johansson</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Josefsson</surname>
              <given-names>B.G.</given-names>
            </name>
            <name>
              <surname>Kristoffersson</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Linnanen</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lisius</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mannikko</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Norden</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ripa</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rognan</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rosendahl</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Skrinjar</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Urbahns</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>52</volume>
          <year>2009</year>
          <fpage>7706</fpage>
          <pub-id pub-id-type="pmid">19954248</pub-id>
        </element-citation>
      </ref>
      <ref id="b0120">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leeson</surname>
              <given-names>P.D.</given-names>
            </name>
            <name>
              <surname>Springthorpe</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <source>Nat. Rev. Drug Disc.</source>
          <volume>6</volume>
          <year>2007</year>
          <fpage>881</fpage>
        </element-citation>
      </ref>
      <ref id="b0125">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Bower</surname>
              <given-names>K.S.</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Lester</surname>
              <given-names>H.A.</given-names>
            </name>
            <name>
              <surname>Dougherty</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Lummis</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <source>Biochemistry</source>
          <volume>47</volume>
          <year>2008</year>
          <fpage>6370</fpage>
          <pub-id pub-id-type="pmid">18498149</pub-id>
        </element-citation>
      </ref>
      <ref id="b0130">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Price</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Lummis</surname>
              <given-names>S.C.</given-names>
            </name>
          </person-group>
          <source>J. Biol. Chem.</source>
          <volume>279</volume>
          <year>2004</year>
          <fpage>23294</fpage>
          <pub-id pub-id-type="pmid">14998995</pub-id>
        </element-citation>
      </ref>
      <ref id="b0135">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marcou</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rognan</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>J. Chem. Inf. Model</source>
          <volume>47</volume>
          <year>2007</year>
          <fpage>195</fpage>
          <pub-id pub-id-type="pmid">17238265</pub-id>
        </element-citation>
      </ref>
      <ref id="b0140">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Graaf</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rognan</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <source>Curr. Pharm. Des.</source>
          <volume>15</volume>
          <year>2009</year>
          <fpage>4026</fpage>
          <pub-id pub-id-type="pmid">20028320</pub-id>
        </element-citation>
      </ref>
      <ref id="b0145">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hibbs</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Sulzenbacher</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Talley</surname>
              <given-names>T.T.</given-names>
            </name>
            <name>
              <surname>Conrod</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kem</surname>
              <given-names>W.R.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Marchot</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Bourne</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <source>EMBO J.</source>
          <volume>28</volume>
          <year>2009</year>
          <fpage>3040</fpage>
          <pub-id pub-id-type="pmid">19696737</pub-id>
        </element-citation>
      </ref>
      <ref id="b0150">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keiser</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Setola</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Irwin</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Laggner</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Abbas</surname>
              <given-names>A.I.</given-names>
            </name>
            <name>
              <surname>Hufeisen</surname>
              <given-names>S.J.</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>N.H.</given-names>
            </name>
            <name>
              <surname>Kuijer</surname>
              <given-names>M.B.</given-names>
            </name>
            <name>
              <surname>Matos</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>T.B.</given-names>
            </name>
            <name>
              <surname>Whaley</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Glennon</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Hert</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>K.L.</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>D.D.</given-names>
            </name>
            <name>
              <surname>Shoichet</surname>
              <given-names>B.K.</given-names>
            </name>
            <name>
              <surname>Roth</surname>
              <given-names>B.L.</given-names>
            </name>
          </person-group>
          <source>Nature</source>
          <volume>462</volume>
          <year>2009</year>
          <fpage>175</fpage>
          <pub-id pub-id-type="pmid">19881490</pub-id>
        </element-citation>
      </ref>
      <ref id="b0155">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keiser</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Irwin</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Shoichet</surname>
              <given-names>B.K.</given-names>
            </name>
          </person-group>
          <source>Biochemistry</source>
          <volume>49</volume>
          <year>2010</year>
          <fpage>10267</fpage>
          <pub-id pub-id-type="pmid">21058655</pub-id>
        </element-citation>
      </ref>
      <ref id="b0160">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gregori-Puigjane</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Mestres</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <source>Comb. Chem. High Throughput Screening</source>
          <volume>11</volume>
          <year>2008</year>
          <fpage>669</fpage>
        </element-citation>
      </ref>
      <ref id="b0165">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Altenbach</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Chandran</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Hsieh</surname>
              <given-names>G.C.</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>L.G.</given-names>
            </name>
            <name>
              <surname>Manelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Milicic</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Marsh</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Strakhova</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Vortherms</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Wakefield</surname>
              <given-names>B.D.</given-names>
            </name>
            <name>
              <surname>Wetter</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Witte</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Honore</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Esbenshade</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Brioni</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Cowart</surname>
              <given-names>M.D.</given-names>
            </name>
          </person-group>
          <source>J. Med. Chem.</source>
          <volume>51</volume>
          <year>2008</year>
          <fpage>7094</fpage>
          <pub-id pub-id-type="pmid">18983139</pub-id>
        </element-citation>
      </ref>
      <ref id="b0170">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strakhova</surname>
              <given-names>M.I.</given-names>
            </name>
            <name>
              <surname>Cuff</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Manelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Carr</surname>
              <given-names>T.L.</given-names>
            </name>
            <name>
              <surname>Witte</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Baranowski</surname>
              <given-names>J.L.</given-names>
            </name>
            <name>
              <surname>Vortherms</surname>
              <given-names>T.A.</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Rundell</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>McPherson</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Adair</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Brito</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Bettencourt</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>B.B.</given-names>
            </name>
            <name>
              <surname>Wetter</surname>
              <given-names>J.M.</given-names>
            </name>
            <name>
              <surname>Marsh</surname>
              <given-names>K.C.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Cowart</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Brioni</surname>
              <given-names>J.D.</given-names>
            </name>
            <name>
              <surname>Esbenshade</surname>
              <given-names>T.A.</given-names>
            </name>
          </person-group>
          <source>Br. J. Pharmacol.</source>
          <volume>157</volume>
          <year>2009</year>
          <fpage>44</fpage>
          <pub-id pub-id-type="pmid">19413570</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="s0010" sec-type="supplementary-material">
      <title>Supplementary data</title>
      <p>
        <supplementary-material content-type="local-data" id="m0005">
          <caption>
            <title>Supplementary data</title>
            <p>Distributions of physical-chemical properties of fragment hits, descriptions of H<sub>4</sub>R and 5-HT<sub>3A</sub>R protein modeling procedures and experimental details of H<sub>4</sub>R and 5-HT<sub>3A</sub>R screens.</p>
          </caption>
          <media xlink:href="mmc1.doc" mimetype="application" mime-subtype="msword"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>M.V. and I.dE. would like to acknowledge EEC grant (Neurocypres) for financial support. C.dG. acknowledges The Netherlands Organization for Scientific Research (VENI Grant 700.59.408) for financial support. This work was furthermore supported by COST Action BM0806COST. SCRL and AJT are Wellcome Trust funded (081925). There are no competing interests.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Figure 1</label>
      <caption>
        <p>(a) SCA plot showing the hit distribution for the H<sub>4</sub>R (Red), the 5-HT<sub>3A</sub>R (blue), the 5-HT<sub>3A</sub>R and H<sub>4</sub>R (green) as well as inactives, compounds which do not bind H<sub>4</sub>R or 5HT<sub>3A</sub>R (grey). Hits presented in <xref rid="t0005" ref-type="table">Table 1</xref> are labeled by their corresponding number. (b) Schematic representation of the overlap between H<sub>4</sub>R and 5<bold>-</bold>HT<sub>3A</sub>R ligands. (c) Distribution of the complexity of H<sub>4</sub>R selective fragments (red line), 5-HT<sub>3A</sub>R selective fragments (blue line), dual H<sub>4</sub>R/5-HT<sub>3A</sub>R fragments (green line), and inactives (dotted grey line).</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Figure 2</label>
      <caption>
        <p>Chemical similarity (ECFP-4 Tc) between dual and selective hits of H<sub>4</sub>R and 5-HT<sub>3A</sub>R and the endogenous ligands of H<sub>4</sub>R (histamine) and 5-HT<sub>3A</sub>R (serotonin).</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Figure 3</label>
      <caption>
        <p>Distribution of physical-chemical properties that discriminate H<sub>4</sub>R selective fragments (red), 5-HT<sub>3A</sub>R selective fragments (blue line), dual H<sub>4</sub>R/5-HT<sub>3A</sub>R fragments (green), and inactives (grey dotted line). Distributions of other physical-chemical properties do not discriminate between the sets as shown in <xref rid="s0010" ref-type="sec">Figure S1</xref></p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Figure 4</label>
      <caption>
        <p>Panel A shows the predicted binding modes of the dual H<sub>4</sub>R/5-HT<sub>3A</sub>R hit <bold>8</bold> (green carbon atoms, see <xref rid="t0005" ref-type="table">Table 1</xref> for molecular structure) in structural models of H<sub>4</sub>R and 5-HT<sub>3A</sub>R. Parts of the backbone of transmembrane (TM) helices 3, 5, 6 and 7 (the top TM3 is not shown for clarity) in H<sub>4</sub>R and loops A, B, C and E of the extracellular ligand-binding domain (ECD) of 5-HT<sub>3A</sub>R are represented by light yellow ribbons. Important binding residues are depicted as ball-and-sticks with grey carbon atoms. Oxygen, nitrogen, and hydrogen atoms are colored red, blue, and cyan, respectively. H-bonds described in the text are depicted by black dots. The molecular interaction fingerprint (IFP)<xref rid="b0135" ref-type="bibr"><sup>27</sup></xref> bit strings of <bold>8</bold> in H<sub>4</sub>R and 5-HT<sub>3A</sub>R are compared in panel B.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Figure 5</label>
      <caption>
        <p>Compounds in preclinical trials by Abbott.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <table-wrap id="t0005" position="float">
      <label>Table 1</label>
      <caption>
        <p>Structures of fragments that bind solely H<sub>4</sub>R (1–3), solely 5-HT<sub>3A</sub>R (4–6) and both H<sub>4</sub>R and 5-HT<sub>3A</sub>R (7–11)</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2">#</th>
            <th rowspan="2">H<sub>4</sub>R/5-HT<sub>3A</sub>R</th>
            <th rowspan="2">Structure</th>
            <th colspan="2" align="center">Affinity (p<italic>K</italic><sub>i</sub>)<hr/></th>
          </tr>
          <tr>
            <th>H<sub>4</sub>R<xref rid="tblfn1" ref-type="table-fn">a</xref></th>
            <th>5-HT<sub>3A</sub>R<xref rid="tblfn3" ref-type="table-fn">c</xref></th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>1</td>
            <td>
              <inline-graphic xlink:href="fx2.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx3.gif"/>
            </td>
            <td>7.0 ± 0.1</td>
            <td>n.a.</td>
          </tr>
          <tr>
            <td>2</td>
            <td>
              <inline-graphic xlink:href="fx2.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx4.gif"/>
            </td>
            <td>6.2 ± 0.1</td>
            <td>n.a.</td>
          </tr>
          <tr>
            <td>3</td>
            <td>
              <inline-graphic xlink:href="fx2.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx5.gif"/>
            </td>
            <td>6.7 ± 0.0</td>
            <td>n.a.</td>
          </tr>
          <tr>
            <td>4</td>
            <td>
              <inline-graphic xlink:href="fx6.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx7.gif"/>
            </td>
            <td>n.a.</td>
            <td>6.1 ± 0.2</td>
          </tr>
          <tr>
            <td>5</td>
            <td>
              <inline-graphic xlink:href="fx6.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx8.gif"/>
            </td>
            <td>n.a.</td>
            <td>6.0 ± 0.0</td>
          </tr>
          <tr>
            <td>6</td>
            <td>
              <inline-graphic xlink:href="fx6.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx9.gif"/>
            </td>
            <td>n.a.</td>
            <td>6.1 ± 0.1</td>
          </tr>
          <tr>
            <td>7</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx11.gif"/>
            </td>
            <td>6.2 ± 0.0</td>
            <td>6.6 ± 0.3</td>
          </tr>
          <tr>
            <td>8</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx12.gif"/>
            </td>
            <td>7.2 ± 0.0</td>
            <td>7.9 ± 0.3</td>
          </tr>
          <tr>
            <td>9</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx13.gif"/>
            </td>
            <td>6.1 ± 0.1<xref rid="tblfn2" ref-type="table-fn">b</xref></td>
            <td>8.8 ± 0.1</td>
          </tr>
          <tr>
            <td>10</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx14.gif"/>
            </td>
            <td>8.2 ± 0.1</td>
            <td>5.9 ± 0.1</td>
          </tr>
          <tr>
            <td>11</td>
            <td>
              <inline-graphic xlink:href="fx10.gif"/>
            </td>
            <td>
              <inline-graphic xlink:href="fx15.gif"/>
            </td>
            <td>6.2 ± 0.1<xref rid="tblfn2" ref-type="table-fn">b</xref></td>
            <td>5.9 ± 0.3</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>n.a.: Non active.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn1">
          <label>a</label>
          <p>Measured by displacement of [<sup>3</sup>H]histamine binding using membranes of HEK293 cells transiently expressing the human H<sub>4</sub>R. p<italic>K</italic><sub>i</sub>’s are calculated from at least three independent measurements as the mean ± SEM.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn2">
          <label>b</label>
          <p>Determined using membranes of SK-N-MC cells transiently expressing the human H<sub>4</sub>R. p<italic>K</italic><sub>i</sub>’s are calculated from at least three independent measurements as the mean ± SEM.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn3">
          <label>c</label>
          <p>p<italic>K</italic><sub>i</sub>: Measured by displacement of [<sup>3</sup>H]granisetron binding using membranes of HEK293 cells expressing the human 5-HT<sub>3A</sub>R. p<italic>K</italic><sub>i</sub>’s are calculated from at least two independent measurements as the mean ± SEM.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>